title: Transfusion requirement can be abolished by epoietin-a and autologous platelet predeposit in patients receiving high dose chemotherapy with stem cell support.
authors.forename: L
authors.initials: L
authors.lastname: Ponchio
authors.forename: A
authors.initials: A
authors.lastname: Zambelli
authors.forename: A
authors.initials: A
authors.lastname: De Stefano
authors.forename: F S
authors.initials: FS
authors.lastname: Robustelli Della Cuna
authors.forename: C
authors.initials: C
authors.lastname: Perotti
authors.forename: P
authors.initials: P
authors.lastname: Pedrazzoli
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001804:Blood Transfusion, Autologous; D001943:Breast Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D017713:Platelet Transfusion; D011994:Recombinant Proteins
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa